Sutro Biopharma STRO Ratios & Valuation
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| Profitability | |||||
| Operating margin | -154.5%+230pp | -384.3%— | —— | -190.3%-31.0pp | |
| Net margin | -186.5%+180pp | -366.6%— | —— | -175.9%-5.3pp | |
| EBITDA margin | -147.4%+225pp | -372.7%— | —— | -181.9%-30.5pp | |
| Free cash flow margin | -172.9%+152pp | -325.2%— | —— | —— | |
| Returns | |||||
| Return on assets | -68.1%-15.1pp | -53%— | —— | -31.9%-3.2pp | |
| Efficiency | |||||
| Asset turnover | 0.4×+0.2× | 0.1×-0.2× | 0.4×+0.2× | 0.2×0.0× | |
| Liquidity | |||||
| Current ratio | 2×-0.6× | 2.6×-1.9× | 4.5×-0.8× | 5.3×+0.1× | |
| Quick ratio | 2×-0.6× | 2.6×-1.9× | 4.5×-0.8× | 5.3×+0.1× | |
| Cash ratio | 0.8×-0.7× | 1.4×+0.7× | 0.7×0.0× | 0.7×0.0× | |
| Leverage | |||||
| Debt-to-assets | 0.1×0.0× | 0.1×0.0× | 0.1×-0.1× | 0.1×0.0× | |
| Per Share | |||||
| Book value per share | -$15.59-370% | $5.76+132% | $2.49-41.9% | $4.28-21.9% | |
| Valuation | |||||
| Market capitalization | $489.66M+624% | $151.72M-42.0% | $261.73M-43.6% | $464.4M-32.5% | |
| Enterprise value | $429.61M-2,600% | -$15.43M-107% | $226.1M-51.6% | $467.58M-34.6% | |
| Price / sales | 4.9×+3.9× | 2.4×+0.7× | 1.7×-5.1× | 6.9×-4.3× | |
| EV / sales | 4.3×+4.6× | -0.2×-1.7× | 1.5×-5.4× | 6.9×-4.7× | |
| Free cash flow yield | -31%+272pp | -133%— | —— | —— | |
| Earnings yield | -31.4%+331pp | -149.9%— | —— | -25.7%-10.3pp |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where do Sutro Biopharma's ratios come from?
- Every ratio is computed from Sutro Biopharma's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
